Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Renal Insufficiency, Chronic 1Non-alcoholic Fatty Liver Disease 1Liver Cirrhosis, Alcoholic 1Hypothermia 1Hepatitis C 1Hepatitis B 1Fibrosis 1End Stage Liver Disease 1Carcinoma, Hepatocellular 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypothermia, Induced × Clear all
NCT03534141 2025-05-16

MHALT

University of California, San Francisco

Phase NA Terminated
175 enrolled 19 charts
GastrointestinalGenitourinary

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Hypothermia, Liver Cirrhosis, Alcoholic, Renal Insufficiency, Chronic, Acute Kidney Injury, End Stage Liver Disease, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡